Foundation Medicine, a Roche subsidiary, agreed to buy Saga Diagnostics for up to $595 million, adding the company’s tumor-informed MRD platform Pathlight to Foundation’s test portfolio. The deal expands Foundation Medicine’s approach to ultra-sensitive monitoring by combining Saga’s Pathlight platform with Roche sequencing and digital PCR infrastructure. Saga’s Pathlight uses whole-genome sequencing and digital PCR to track structural variants, and the acquisition is expected to close in Q3 with integration of Pathlight into Foundation Medicine afterward. Foundation said it plans to leverage its commercial scale to broaden Pathlight’s reach, including international deployment and additional cancer indications beyond early breast and colorectal MRD monitoring. For the MRD market, the transaction signals consolidation around tumor-informed, ultra-sensitive workflows and reinforces a shift toward scalable, decentralized testing architectures supported by sequencing and liquid-biology platforms.